| Literature DB >> 31466586 |
Erik Peterson1, Jason Weed1, Kristen Lo Sicco1, Jo-Ann Latkowski2.
Abstract
Cutaneous T cell lymphoma (CTCL) represents a heterogeneous group of extranodal non-Hodgkin lymphomas in which monoclonal T lymphocytes infiltrate the skin. The mechanism of CTCL development is not fully understood, but likely involves dysregulation of various genes and signaling pathways. A variety of treatment modalities are available, and although they can induce remission in most patients, the disease may recur after treatment cessation. Owing to relatively low incidence and significant chronicity of disease, and the high morbidity of some therapeutic regimens, further clinical trials are warranted to better define the ideal treatment option for each subtype of CTCL.Entities:
Keywords: CTCL treatment; Clinical correlations; Cutaneous T cell lymphoma; Histology; Mycosis fungoides; Overview
Mesh:
Substances:
Year: 2019 PMID: 31466586 DOI: 10.1016/j.det.2019.05.007
Source DB: PubMed Journal: Dermatol Clin ISSN: 0733-8635 Impact factor: 3.478